As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014.
Through this newly named report series, the PMPRB monitors and reports on:
the latest developments in generic drug pricing and markets ... Read More
12
Feb2016
12
Feb2016
Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews.
As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ... Read More
02
Feb2016
In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback ... Read More
20
Jan2016
Order your subscription today to gain instant online access!
The C-MAP™ Canadian Drug Benefit Plans Reference Guide is the authoritative source for comprehensive and up-to-date information on Canadian reimbursement and market access for pharmaceutical market access specialists.
The publication highlights each of the relevant agencies, organizations and drug plans operating in the ... Read More
21
Dec2015
The Patented Medicines Prices Review Board (PMPRB) has released their highly anticipated Strategic Plan 2015-2018. The PMPRB’s three-year strategic plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of ... Read More
14
Dec2015
The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, has released the Annual Report for the year ended December 31, 2014. This year, the format has been updated, adopting a more user-friendly design highlighting the PMPRB activities and emphasizing important trends.
Below ... Read More
14
Dec2015
CADTH is currently updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. To help with this initiative, CADTH is inviting interested stakeholders to provide input. These guidelines detail best practices for conducting economic evaluations and are used to standardize and facilitate economic evaluations while ... Read More
25
Nov2015
PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers. With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ... Read More
13
Nov2015
2015 FCA 249 Attorney General of Canada v Sandoz (A-302-14) & v ratiopharm (now Teva) (A-303-14).
The central issue in both appeals is whether the Federal Court judge properly held that Sandoz and ratiopharm (collectively the respondents) fell outside of the jurisdiction of the Board as they were not “patentees” within ... Read More
03
Nov2015
On Friday, October 30, 2015 PDCI presented a webinar entitled “Market Access Climate Change: the Evolving Impact of Product Listing Agreements”.
The purpose of this webinar was to:
Shed light on the recent developments at the pCPA; and
Enhance the understanding of the growing practice of PLA negotiations in the private payer ... Read More